Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $32.71

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $32.7143.

A number of equities research analysts have issued reports on AVTX shares. BTIG Research reissued a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a research note on Monday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Avalo Therapeutics in a research note on Thursday, January 15th.

Institutional Trading of Avalo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AVTX. BIT Capital GmbH bought a new stake in Avalo Therapeutics in the third quarter worth approximately $25,000. PFS Partners LLC lifted its stake in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares during the last quarter. Quadrature Capital Ltd bought a new stake in Avalo Therapeutics in the second quarter worth $55,000. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth $56,000. Finally, Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics during the third quarter worth $143,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Price Performance

NASDAQ:AVTX opened at $15.75 on Monday. The stock has a market cap of $291.53 million, a PE ratio of -2.94 and a beta of 0.84. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72. The stock’s 50-day moving average is $17.63 and its two-hundred day moving average is $13.55.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.52). On average, equities research analysts anticipate that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.